FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011250400> ?p ?o ?g. }

• W2011250400 endingPage "65" @default.
• W2011250400 startingPage "58" @default.
• W2011250400 abstract "Objectives To evaluate the effect of psychotropics on stimulated salivary flow rate (SSFR), total proteins, urea and calcium concentration, α-amylase activity, pH, saliva buffer capacity (SBC), and the prevalence of xerostomia in psychotropic users and its relationship with low SSFR and/or hyposalivation. Study design Thirty-three subjects were allocated to 4 groups: I (control): II (psychotropic users); III (subjects of group II using only selective serotonin reuptake inhibitors [SSRIs]); and IV (subjects of group II using SSRIs at recommended initial dose). The SBC was obtained by titrimetry and salivary composition by colorimetric method. Results Group II presented a significant decrease (P = .0203), of 33.85% in SSFR compared with group I. Mean SSFR values in groups III and IV showed no significant difference compared with control group (P > .05). Xerostomia was observed in 37.50%, 38.46%, and 50% of subjects in groups II, III, and IV, respectively. Biochemical composition, pH, and SBC were not significantly affected (P > .05) by the use of psychotropics. Conclusions Xerostomia was associated with a decrease in SSFR and not with alterations in biochemical composition. Even when using the latest-generation drugs, there were complaints of xerostomia associated with decrease in SSFR. To evaluate the effect of psychotropics on stimulated salivary flow rate (SSFR), total proteins, urea and calcium concentration, α-amylase activity, pH, saliva buffer capacity (SBC), and the prevalence of xerostomia in psychotropic users and its relationship with low SSFR and/or hyposalivation. Thirty-three subjects were allocated to 4 groups: I (control): II (psychotropic users); III (subjects of group II using only selective serotonin reuptake inhibitors [SSRIs]); and IV (subjects of group II using SSRIs at recommended initial dose). The SBC was obtained by titrimetry and salivary composition by colorimetric method. Group II presented a significant decrease (P = .0203), of 33.85% in SSFR compared with group I. Mean SSFR values in groups III and IV showed no significant difference compared with control group (P > .05). Xerostomia was observed in 37.50%, 38.46%, and 50% of subjects in groups II, III, and IV, respectively. Biochemical composition, pH, and SBC were not significantly affected (P > .05) by the use of psychotropics. Xerostomia was associated with a decrease in SSFR and not with alterations in biochemical composition. Even when using the latest-generation drugs, there were complaints of xerostomia associated with decrease in SSFR." @default.
• W2011250400 created "2016-06-24" @default.
• W2011250400 creator A5003776538 @default.
• W2011250400 creator A5016823125 @default.
• W2011250400 creator A5041643296 @default.
• W2011250400 creator A5056685188 @default.
• W2011250400 creator A5056963053 @default.
• W2011250400 creator A5057891268 @default.
• W2011250400 creator A5071285118 @default.
• W2011250400 date "2008-07-01" @default.
• W2011250400 modified "2023-10-16" @default.
• W2011250400 title "Effects of antidepressants and benzodiazepines on stimulated salivary flow rate and biochemistry composition of the saliva" @default.
• W2011250400 cites W1560059328 @default.
• W2011250400 cites W1565437970 @default.
• W2011250400 cites W1970894020 @default.
• W2011250400 cites W1975634874 @default.
• W2011250400 cites W198529824 @default.
• W2011250400 cites W1993335904 @default.
• W2011250400 cites W1993941170 @default.
• W2011250400 cites W1997563861 @default.
• W2011250400 cites W2001507393 @default.
• W2011250400 cites W2015172852 @default.
• W2011250400 cites W2017631658 @default.
• W2011250400 cites W2017928833 @default.
• W2011250400 cites W2019933157 @default.
• W2011250400 cites W2030993359 @default.
• W2011250400 cites W2042358844 @default.
• W2011250400 cites W2043718585 @default.
• W2011250400 cites W2068876933 @default.
• W2011250400 cites W2069164490 @default.
• W2011250400 cites W2084834596 @default.
• W2011250400 cites W2105382071 @default.
• W2011250400 cites W2110476213 @default.
• W2011250400 cites W2116742631 @default.
• W2011250400 cites W2132666903 @default.
• W2011250400 cites W2140387881 @default.
• W2011250400 cites W2144585379 @default.
• W2011250400 cites W2189659700 @default.
• W2011250400 cites W4252061555 @default.
• W2011250400 cites W4299312607 @default.
• W2011250400 doi "https://doi.org/10.1016/j.tripleo.2007.11.008" @default.
• W2011250400 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18329910" @default.
• W2011250400 hasPublicationYear "2008" @default.
• W2011250400 type Work @default.
• W2011250400 sameAs 2011250400 @default.
• W2011250400 citedByCount "58" @default.
• W2011250400 countsByYear W20112504002012 @default.
• W2011250400 countsByYear W20112504002013 @default.
• W2011250400 countsByYear W20112504002014 @default.
• W2011250400 countsByYear W20112504002015 @default.
• W2011250400 countsByYear W20112504002016 @default.
• W2011250400 countsByYear W20112504002017 @default.
• W2011250400 countsByYear W20112504002018 @default.
• W2011250400 countsByYear W20112504002019 @default.
• W2011250400 countsByYear W20112504002020 @default.
• W2011250400 countsByYear W20112504002021 @default.
• W2011250400 countsByYear W20112504002022 @default.
• W2011250400 countsByYear W20112504002023 @default.
• W2011250400 crossrefType "journal-article" @default.
• W2011250400 hasAuthorship W2011250400A5003776538 @default.
• W2011250400 hasAuthorship W2011250400A5016823125 @default.
• W2011250400 hasAuthorship W2011250400A5041643296 @default.
• W2011250400 hasAuthorship W2011250400A5056685188 @default.
• W2011250400 hasAuthorship W2011250400A5056963053 @default.
• W2011250400 hasAuthorship W2011250400A5057891268 @default.
• W2011250400 hasAuthorship W2011250400A5071285118 @default.
• W2011250400 hasConcept C126322002 @default.
• W2011250400 hasConcept C134018914 @default.
• W2011250400 hasConcept C138885662 @default.
• W2011250400 hasConcept C185592680 @default.
• W2011250400 hasConcept C2780365088 @default.
• W2011250400 hasConcept C40231798 @default.
• W2011250400 hasConcept C41895202 @default.
• W2011250400 hasConcept C504460877 @default.
• W2011250400 hasConcept C519063684 @default.
• W2011250400 hasConcept C55493867 @default.
• W2011250400 hasConcept C71924100 @default.
• W2011250400 hasConceptScore W2011250400C126322002 @default.
• W2011250400 hasConceptScore W2011250400C134018914 @default.
• W2011250400 hasConceptScore W2011250400C138885662 @default.
• W2011250400 hasConceptScore W2011250400C185592680 @default.
• W2011250400 hasConceptScore W2011250400C2780365088 @default.
• W2011250400 hasConceptScore W2011250400C40231798 @default.
• W2011250400 hasConceptScore W2011250400C41895202 @default.
• W2011250400 hasConceptScore W2011250400C504460877 @default.
• W2011250400 hasConceptScore W2011250400C519063684 @default.
• W2011250400 hasConceptScore W2011250400C55493867 @default.
• W2011250400 hasConceptScore W2011250400C71924100 @default.
• W2011250400 hasIssue "1" @default.
• W2011250400 hasLocation W20112504001 @default.
• W2011250400 hasLocation W20112504002 @default.
• W2011250400 hasOpenAccess W2011250400 @default.
• W2011250400 hasPrimaryLocation W20112504001 @default.
• W2011250400 hasRelatedWork W1966504330 @default.
• W2011250400 hasRelatedWork W1979139803 @default.
• W2011250400 hasRelatedWork W2003842308 @default.
• W2011250400 hasRelatedWork W2037631372 @default.
• W2011250400 hasRelatedWork W2040058909 @default.

• next